A Study Assessing the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Open-Label, Continuous, Stepwise, Dose Increasing, Subcutaneous Infusion of Cenderitide Via the Insulet Drug Delivery System in Subjects With Stable, Chronic Heart Failure
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2017
At a glance
- Drugs Cenderitide (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Capricor Therapeutics
- 10 Jun 2017 Biomarkers information updated
- 31 Jan 2017 Status changed from active, no longer recruiting to completed.
- 23 Apr 2015 According to Capricor Therapeutics media release, company completes enrolment of this trial.